The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Macleods Pharmaceuticals Limited is initiating a Retail/Pharmacy level Recall of Levothyroxine sodium tablets USP 150 mcg.

This recall is being initiated due to an Out-of-Specification (OOS) assay result. The observed assay value was 94.8%, which fails to meet the established specification limits of 95.0% to 105.0%.

The marginal decrease in the assay value for Levothyroxine Sodium Tablets USP 150 mcg (Batch No.: 16240062A) is unlikely to affect systemic absorption or therapeutic efficacy; therefore, it does not pose a significant risk to patient safety. Hence, as a precautionary measure, the subject batch is proposed to a recall from the market as a Retail level (Class III recall).

The batch was distributed during the period of 25th November 2024 to 25th February 2025.

PRODUCT: Levothyroxine sodium tablets US 150 mcg

NDC NUMBER: 33342-401-44

LOT NUMBER: 16240062A

EXPIRY DATE: 03/2026